These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 16140593)
1. A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life. Kerr MP; Baker GA; Brodie MJ Epilepsy Behav; 2005 Nov; 7(3):472-80. PubMed ID: 16140593 [TBL] [Abstract][Full Text] [Related]
2. Topiramate: a review of its use in childhood epilepsy. Ormrod D; McClellan K Paediatr Drugs; 2001; 3(4):293-319. PubMed ID: 11354701 [TBL] [Abstract][Full Text] [Related]
3. Topiramate in patients with epilepsy and intellectual disability. Martin P; Schreiner A; Rettig K; Schäuble B Epilepsy Behav; 2009 Mar; 14(3):496-502. PubMed ID: 19162230 [TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Sharief M; Viteri C; Ben-Menachem E; Weber M; Reife R; Pledger G; Karim R Epilepsy Res; 1996 Nov; 25(3):217-24. PubMed ID: 8956919 [TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Sachdeo RC; Glauser TA; Ritter F; Reife R; Lim P; Pledger G Neurology; 1999 Jun; 52(9):1882-7. PubMed ID: 10371538 [TBL] [Abstract][Full Text] [Related]
6. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Storey JR; Calder CS; Hart DE; Potter DL Headache; 2001; 41(10):968-75. PubMed ID: 11903524 [TBL] [Abstract][Full Text] [Related]
7. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Privitera M; Fincham R; Penry J; Reife R; Kramer L; Pledger G; Karim R Neurology; 1996 Jun; 46(6):1678-83. PubMed ID: 8649569 [TBL] [Abstract][Full Text] [Related]
8. Long-term assessment of topiramate for epilepsy: an open-label, single-arm, multicentre, prospective study in a naturalistic setting. Hufnagel A; Kowalik A; Rettig K; Schreiner A; Schäuble B; Clin Drug Investig; 2011 Nov; 31(11):779-90. PubMed ID: 21967069 [TBL] [Abstract][Full Text] [Related]
9. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Gilliam FG; Veloso F; Bomhof MA; Gazda SK; Biton V; Ter Bruggen JP; Neto W; Bailey C; Pledger G; Wu SC Neurology; 2003 Jan; 60(2):196-202. PubMed ID: 12552030 [TBL] [Abstract][Full Text] [Related]
11. Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures. Chung SS; Hogan RE; Blatt I; Lawson P B; Nguyen H; Clark AM; Anders B; Halvorsen MB; Epilepsy Behav; 2016 Jun; 59():13-20. PubMed ID: 27084978 [TBL] [Abstract][Full Text] [Related]
12. A pooled analysis of adjunctive topiramate in refractory partial epilepsy. Peeters K; Adriaenssen I; Wapenaar R; Neto W; Pledger G Acta Neurol Scand; 2003 Jul; 108(1):9-15. PubMed ID: 12807387 [TBL] [Abstract][Full Text] [Related]
13. A multicenter, outpatient, open-label study to evaluate the dosing, effectiveness, and safety of topiramate as monotherapy in the treatment of epilepsy in clinical practice. Sankar R; Ramsay E; McKay A; Hulihan J; Wiegand F; Epilepsy Behav; 2009 Aug; 15(4):506-12. PubMed ID: 19643672 [TBL] [Abstract][Full Text] [Related]